

# Elder Pharmaceuticals Ltd.

Registered Office: "Elder House", C-9, Dalia Industrial Estate,  
Off. Veera Desai Road, Andheri (W), Mumbai-400 053.

## Consolidated Unaudited Financial Results (Provisional) for the Quarter Ended 30th June, 2010

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30.06.2010 (Unaudited)	Corresponding 3 months ended in the previous year 30.06.2010 (Unaudited)	Previous Accounting year ended 31.03.2010 (Unaudited)
1.	a) Net sales / Income from operations	19430.06	16289.85	70197.54
	b) Other operating income	19.75	6.46	44.70
	<b>Total Income ( a + b )</b>	<b>19449.81</b>	<b>16296.31</b>	<b>70242.24</b>
2.	Expenditure			
	a) Increase ( - ) / Decrease ( + ) in stock in trade and work in process.	-617.07	-652.16	-5133.95
	b) Consumption of Raw Materials	3308.80	2741.77	11616.49
	c) Purchase of traded goods	6489.79	5627.19	26650.33
	d) Employees cost	2711.30	2491.27	9915.13
	e) Depreciation	504.02	342.37	1503.43
	f) Other Expenditure	3780.49	3391.33	14257.25
	<b>g) Total</b>	<b>16177.33</b>	<b>13941.77</b>	<b>58808.68</b>
3.	Profit from operations before other income, interest & exceptional items	3272.48	2354.54	11433.56
4.	Other income	206.09	92.32	802.42
5.	Profit before interest & exceptional items	3478.57	2446.86	12235.98
6.	Interest	1416.20	1048.77	5234.51
7.	Profit after interest but before exceptional items	2062.37	1398.09	7001.47
8.	Exceptional items (Refer note number 6 below)	160.06	0.00	475.61
9.	Profit from ordinary activities before tax	1902.31	1398.09	6525.86
10.	Tax expenses (Refer note number 7 below)	300.00	250.00	1000.00
11.	Net profit from ordinary activities after tax but before minority interest.	1602.31	1148.09	5525.86
12.	Extraordinary items	0.00	0.00	0.00
13.	Net profit for the period	1602.31	1148.09	5525.86
14.	Share of minority interest in (profit) / loss	65.89	0.00	0.00
15.	Net profit for the period after minority interest	<b>1668.20</b>	<b>1148.09</b>	<b>5525.86</b>
16.	Paid up equity share capital (Face value Rs.10/-)	1885.74	1885.74	1885.74
17.	Reserves excluding revaluation reserves as per Balance sheet of previous accounting year	-	-	-
18.	Earnings Per Share ( EPS )			
	a) Basic & diluted EPS before extraordinary items for the period, for the year to date & for the previous year	8.85	3.09	29.30
	b) Basic & diluted EPS after extraordinary items for the period, for the year to date & for the previous year	8.85	6.09	29.30
19.	Public shareholding			
	- Number of shares	11215678	11335327	11215678
	- Percentage of shareholding	59.48	60.11	59.47
20.	Promoters & Promoter Group Shareholding			
	A) Pledged/Encumbered			
	- Number of Shares	5767659	4387900	4534279
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	75.48	58.33	59.34
	- Percentage of shares (as a % of the total share capital of the company)	30.58	23.27	24.04
	B) Non-Encumbered			
	- Number of Shares	1874149	3134259	3107529
	- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	24.52	41.67	40.66
	- Percentage of Shares (as a % of total share capital of the company)	9.94	16.62	16.48

- NOTES:**
- The above results were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on 27th July 2010.
  - The statutory Auditors have carried out a limited review of the unaudited (provisional) financial results for the quarter ended 30th June, 2010.
  - The consolidated results of the Company include the result of the subsidiary Elder Biomedica AD, Bulgaria (61%) and Elder FZCO, Dubai (100%).
  - Standalone financial results are available on the Company's website [www.elderindia.com](http://www.elderindia.com). For the quarter ended 30th June 2010 on a standalone basis the Company has reported turnover of Rs.19108.96 lakhs, Profit before tax of Rs.2187.87 lakhs, and profit after tax of Rs.1887.87 lakhs.
  - The Company operate in Pharmaceutical segment only. Hence, pursuant to accounting standard AS-17 on segment reporting, segmental information is not required to be given.
  - Exceptional item of Rs.160.06 lacs pertains to exchange loss on quarterly installment of ECB repayment.
  - Provision for Tax includes current tax and deferred tax.
  - Investor complaints: Pending at the beginning of the quarter - Nil. Received during the quarter - 7. Pending at the end of the quarter - Nil.
  - Previous years figures have been regrouped/rearranged wherever necessary.